Financial Review: Compass Therapeutics (NASDAQ:CMPX) versus AVAX Technologies (OTCMKTS:AVXT)

Compass Therapeutics (NASDAQ:CMPX) and AVAX Technologies (OTCMKTS:AVXT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Insider and Institutional Ownership

68.4% of Compass Therapeutics shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 6.0% of AVAX Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Compass Therapeutics and AVAX Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850,000.00	436.45	-$66.49 million	($0.41)	-5.02
AVAX Technologies	N/A	N/A	N/A	N/A	N/A

AVAX Technologies has lower revenue, but higher earnings than Compass Therapeutics.

Analyst Ratings

This is a summary of current ratings and price targets for Compass Therapeutics and AVAX Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1	1	11	1	2.86
AVAX Technologies	0	0	0	0	0.00

Compass Therapeutics presently has a consensus price target of $12.91, indicating a potential upside of 526.65%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than AVAX Technologies.

Profitability

This table compares Compass Therapeutics and AVAX Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
AVAX Technologies	N/A	N/A	N/A

Summary

Compass Therapeutics beats AVAX Technologies on 7 of the 9 factors compared between the two stocks.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

About AVAX Technologies

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company’s product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.